Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2023-181076

Published: 2023

Journal Articles

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Blood (2023) 142 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2023-186777

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Blood (2023) 142 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2023-179852

Published: 2023

Journal Articles

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4230.

https://doi.org/10.1182/blood-2023-185484

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on the Immune Reconstitution and the Incidence of Infectious Complications

Blood (2023) 142 (Supplement 1): 2200.

https://doi.org/10.1182/blood-2023-186687

Published: 2023

Journal Articles

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Blood (2022) 140 (Supplement 1): 7616–7618.

https://doi.org/10.1182/blood-2022-167051

Published: 2022

Journal Articles

Endotheliopathy, Innate-Immune Activation and Hemostatic Misbalance Underlying CAR-T Cell Toxicities: Tools for Early and Differential Diagnosis

Ana Belén Moreno-Castaño, Sara Fernandez, Marta Palomo, Julia Martinez-Sanchez, Alex Ramos, Patricia Molina, Marc Pino, Valentín Ortiz-Maldonado, Julio Delgado, Carlos Fernández De Larrea, Álvaro Urbano-Ispizua, Gines Escolar, Enric Carreras, Francesc Fernández-Avilés, Pedro Castro, Maribel Diaz-Ricart

Blood (2022) 140 (Supplement 1): 7427–7428.

https://doi.org/10.1182/blood-2022-169293

Published: 2022

Journal Articles

Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Blood (2022) 140 (Supplement 1): 4730–4732.

https://doi.org/10.1182/blood-2022-170498

Published: 2022

Journal Articles

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

María Queralt Salas, Paola Charry, Nuria Martínez-Cibrian, María Suárez-Lledó, Luis Gerardo Rodríguez-Lobato, Marc Brusosa, María Teresa Solano, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Jordi Arcarons, Noemí Llobet, Laura Rosinol Dachs, Jordi Esteve, Álvaro Urbano-Ispizua, Enric Carreras, Francesc Fernández-Avilés, Maria Carmen Martinez Munoz, Montserrat Rovira

Blood (2022) 140 (Supplement 1): 4772–4773.

https://doi.org/10.1182/blood-2022-170407

Published: 2022

Journal Articles

Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Paola Andrea Charry, Maria Queralt Salas, Alexandra Pedraza, María Suárez-Lledó, Nuria Martínez-Cibrian, Teresa Solano, Ariadna Domenech, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Laura Rosinol, Francesc Fernández-Avilés, Gonzalo Gutiérrez-García, Enric Carreras, Jordi Esteve, Álvaro Urbano-Ispizua, Montserrat Rovira, Carmen Martínez

Blood (2021) 138 (Supplement 1): 2760.

https://doi.org/10.1182/blood-2021-153366

Published: 2021

Journal Articles

Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era

Blood (2021) 138 (Supplement 1): 3925.

https://doi.org/10.1182/blood-2021-153069

Published: 2021

Journal Articles

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the Grupo Español De Trasplante Hematopoyético (GETH)

Blood (2018) 132 (Supplement 1): 200.

https://doi.org/10.1182/blood-2018-200

Published: 2018

Journal Articles

Post-Transplant High-Dose Cyclophosphamide Overcomes the Detrimental Effect of a Single-Locus HLA Mismatched in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Patricia Ferraz, MD, Arturo Pereira, MD PhD, María Suárez-Lledó, MD, Gonzalo Gutiérrez-García, MD, Francesc Fernández-Avilés, MD, Laura Rosinol, MD PhD, Teresa Solano, Noemí Llobet, Carla Ramos, Pedro Marín, MD, Alvaro Urbano-Ispizua, MD, Montserrat Rovira, MD, Carmen Martinez, MD PhD

Blood (2018) 132 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2018-99-112985

Published: 2018

Journal Articles

Response to Proteosome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study

Blood (2016) 128 (22): 3436.

https://doi.org/10.1182/blood.V128.22.3436.3436

Published: 2016

Journal Articles

Association Between Uric Acid Levels and Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation

Nuria Martinez-Cibrian, Teresa Garrido, Arturo Pereira, Mauricio Sarmiento, Jose Antonio Pérez-Simón, Rocio Parody, MD, Estefania Perez, Oriana Lopez, Carlos Solano, Jose Luis Piñana, Montserrat Rovira, Francesc Fernandez-Avilés, Maria Suarez-Lledo, Alvaro Urbano-Ispizua, Carmen Martinez, MD PhD

Blood (2015) 126 (23): 5464.

https://doi.org/10.1182/blood.V126.23.5464.5464

Published: 2015

Journal Articles

At-Home Management of Adult Patients Following Consolidation Chemotherapy for Acute Myeloid Leukemia

Anna Gaya, MD, Jordina Rovira, MD, Cristina Moreno, Cristina Gallego, Adelina Hernando, Susana Segura, Nacira Arab, Pilar Ayora, Montserrat Carreño, Núria Martínez-Cibrián, MD, Jordi Esteve, MD PhD, Francesc Fernández-Avilés, MD PhD

Blood (2014) 124 (21): 3692.

https://doi.org/10.1182/blood.V124.21.3692.3692

Published: 2014

Journal Articles

Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome

Rocío Parody, MDPhD, Dolores Caballero, Martinez Carmen, MD PhD, Rodrigo Martino, MD PhD, Carlos Solano, Pere Barba, MD, Lucía López-Corral, MD PhD, Oriana Lopez Godino, MD, Lourdes Vazquez, MD, Montserrat Rovira, MD PhD, Francesc Fernandez-Avilés, Albert Esquirol, MD, Irene García Cadenas, José Luís Piñana, David Valcarcel, MD PhD, Francisco J. Marquez-Malaver, Jose Antonio Perez-Simón, MDPhD

Blood (2014) 124 (21): 1165.

https://doi.org/10.1182/blood.V124.21.1165.1165

Published: 2014

Journal Articles

The Combination of the EBMT Score and the HCT-CI Is Not Better Than the HCT-CI Alone in the Prediction of NRM and OS in Patients Undergoing Allogeneic Hematopoietic Transplantation with Reduced-Toxicity Conditioning

Pere Barba, David Valcarcel, MD, Lucía López-Corral, MD, Francesc fernandez-Aviles, Rodrigo Martino, MD, PhD, Monica Cabrero, Montserrat Rovira, jose Luis Pinana, Salut Brunet, Enric Carreras, MD, PhD, maria Dolores Caballero, Jorge Sierra, MD

Blood (2012) 120 (21): 1925.

https://doi.org/10.1182/blood.V120.21.1925.1925

Published: 2012

Journal Articles

Hepatic Toxicity After Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation: Incidence, Characteristics and Risk Factors In a Cohort of 452 Patients.

Pere Barba, Rodrigo Martino, jose Luis Pinana, Jose Antonio Perez-Simon, Francesc fernandez-Aviles, David Valcarcel, Montserrat Rovira, Lucia Lopez-Anglada, Silvana Novelli, Enric Carreras, Jorge Sierra, MD

Blood (2010) 116 (21): 3495.

https://doi.org/10.1182/blood.V116.21.3495.3495

Published: 2010

Journal Articles

Genetic Variability In the Transcriptional Factor EP300 Strongly Influences the Clinical Outcome of Allogeneic Stem Cell Transplantation (Allo-SCT)

Beatriz Martin-Antonio, PhD, Rocio Cardesa, Isabel Álvarez, Francisco Márquez-Malaver, Alicia Báez, Magdalena Carmona, MD, Jose Falantes, Francesc fernandez-Aviles, Carmen Martinez, Montserrat Rovira, MD, Ildefonso Espigado, MD, PhD, Alvaro Urbano-Ispizua, MD, PhD

Blood (2010) 116 (21): 527.

https://doi.org/10.1182/blood.V116.21.527.527

Published: 2010

NARROW

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on the Immune Reconstitution and the Incidence of Infectious Complications

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Endotheliopathy, Innate-Immune Activation and Hemostatic Misbalance Underlying CAR-T Cell Toxicities: Tools for Early and Differential Diagnosis

Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the Grupo Español De Trasplante Hematopoyético (GETH)

Post-Transplant High-Dose Cyclophosphamide Overcomes the Detrimental Effect of a Single-Locus HLA Mismatched in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Response to Proteosome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study

Association Between Uric Acid Levels and Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation

At-Home Management of Adult Patients Following Consolidation Chemotherapy for Acute Myeloid Leukemia

Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome

The Combination of the EBMT Score and the HCT-CI Is Not Better Than the HCT-CI Alone in the Prediction of NRM and OS in Patients Undergoing Allogeneic Hematopoietic Transplantation with Reduced-Toxicity Conditioning

Hepatic Toxicity After Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation: Incidence, Characteristics and Risk Factors In a Cohort of 452 Patients.

Genetic Variability In the Transcriptional Factor EP300 Strongly Influences the Clinical Outcome of Allogeneic Stem Cell Transplantation (Allo-SCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only